State Street
RXRX icon

State Street’s Recursion Pharmaceuticals RXRX Stock Holding History

State Street’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$87.5M Buy
28,490,638
+3,156,750
+12% +$12.2M ﹤0.01% 1445
2025
Q4 		$104M Buy
25,333,888
+7,064,963
+39% +$35M ﹤0.01% 1334
2025
Q3 		$89.2M Buy
18,268,925
+7,089,386
+63% +$37.2M ﹤0.01% 1393
2025
Q2 		$56.6M Sell
11,179,539
-1,905,719
-15% -$9.36M ﹤0.01% 1610
2025
Q1 		$69.2M Buy
13,085,258
+506,898
+4% +$3.7M ﹤0.01% 1474
2024
Q4 		$85M Sell
12,578,360
-291,912
-2% -$1.96M ﹤0.01% 1440
2024
Q3 		$84.8M Buy
12,870,272
+4,120,685
+47% +$29.5M ﹤0.01% 1418
2024
Q2 		$65.6M Sell
8,749,587
-1,602,769
-15% -$14M ﹤0.01% 1517
2024
Q1 		$103M Sell
10,352,356
-1,799,290
-15% -$20M ﹤0.01% 1284
2023
Q4 		$120M Buy
12,151,646
+394,558
+3% +$2.81M 0.01% 1172
2023
Q3 		$89.9M Buy
11,757,088
+6,059,156
+106% +$60.4M 0.01% 1252
2023
Q2 		$42.6M Sell
5,697,932
-674,583
-11% -$4.72M ﹤0.01% 1768
2023
Q1 		$42.5M Sell
6,372,515
-1,498,443
-19% -$11.9M ﹤0.01% 1759
2022
Q4 		$60.7M Buy
7,870,958
+3,315,199
+73% +$32.5M ﹤0.01% 1500
2022
Q3 		$48.5M Buy
4,555,759
+2,430,027
+114% +$24.6M ﹤0.01% 1616
2022
Q2 		$17.3M Buy
2,125,732
+206,998
+11% +$1.39M ﹤0.01% 2353
2022
Q1 		$13.7M Sell
1,918,734
-2,737,993
-59% -$29.1M ﹤0.01% 2645
2021
Q4 		$79.8M Buy
4,656,727
+3,012,233
+183% +$56.7M ﹤0.01% 1471
2021
Q3 		$37.8M Buy
1,644,494
+1,267,062
+336% +$35.9M ﹤0.01% 2013
2021
Q2 		$13.8M Buy
+377,432
New +$11.2M ﹤0.01% 2722

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

State Street's RXRX Position: Q1 2026 in Review

State Street increased its Recursion Pharmaceuticals (RXRX) stake by 12% in Q1 2026, buying an estimated $12.2M and bringing the position to 28,490,638 shares worth $87.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1445.

State Street first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $120M in Q4 2023. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • State Street held 28,490,638 shares of Recursion Pharmaceuticals worth $87.5M as of Q1 2026.
  • State Street bought 3,156,750 Recursion Pharmaceuticals shares in Q1 2026, an estimated $12.2M.
  • Recursion Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q1 2026, its #1445 holding.
  • State Street first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • State Street's Recursion Pharmaceuticals position peaked at $120M in Q4 2023.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.